Peptide half-life and pharmacokinetics.

What half-life actually means.

Elimination half-life is the time it takes for the concentration of a drug in plasma to fall by half. It is a property of the molecule and the person, not of the dose. Doubling the dose does not change the half-life; it changes the starting concentration. This single fact explains most of what follows, because it means the dosing interval is dictated by how fast the body removes the compound rather than by how much is given.

Because elimination is usually first-order, the decay is exponential rather than linear. Each half-life removes half of what remains, so the absolute amount cleared per unit time falls as the concentration falls. The practical consequence is that a drug does not disappear at a steady rate and then stop. It tails off, and the tail is long relative to the half-life.

Two implications follow that people frequently miss. First, a compound with a one week half-life is still climbing toward its full concentration more than a month into use, which is one reason effects and side effects both evolve over the first weeks. Second, stopping does not mean the compound is gone. It means input stopped while a five-half-life washout begins.

Why native peptides are destroyed in minutes.

Peptides are chains of amino acids joined by peptide bonds, which is exactly what the body's digestive and regulatory machinery is built to cut. Endogenous signalling peptides are meant to be transient: a hormone that persisted for days would be useless as a moment to moment signal. Evolution therefore paired every regulatory peptide with efficient clearance, and that clearance is the central obstacle to using peptides as drugs.

The best-documented example is GLP-1 itself. Deacon and colleagues showed in 1995 that both subcutaneously and intravenously administered GLP-1 is rapidly degraded from the amino terminus in people with type 2 diabetes and in healthy subjects, with dipeptidyl peptidase-4 cleaving the first two residues and producing a metabolite that is not an agonist at the receptor. The intact hormone survives on the order of a couple of minutes. This is why native GLP-1 was never a plausible therapy, and why an entire drug class (the DPP-4 inhibitors) exists purely to slow that one enzyme.

DPP-4 is a specific case of a general problem. Peptides in circulation face aminopeptidases and carboxypeptidases trimming from the ends, endopeptidases cutting internally, and, for small peptides, glomerular filtration in the kidney, which readily clears molecules well below the albumin size threshold. A short unmodified peptide is therefore attacked chemically and removed physically at the same time.

The engineering that fixes it.

Modern peptide therapeutics exist because medicinal chemists found ways to defeat those clearance routes without destroying receptor binding. The strategies fall into a small number of families, and a single molecule usually combines several. Review work on half-life extension of biotherapeutics catalogues these approaches along with their trade-offs, which include immunogenicity, manufacturing complexity, and reduced potency per molecule.

Esterification, and why testosterone is dosed the way it is.

Injectable testosterone illustrates depot kinetics cleanly. Testosterone itself has a very short circulating half-life. Attaching an ester (propionate, cypionate, enanthate, undecanoate) produces a more lipophilic molecule that stays in the oil depot at the injection site and is released gradually into circulation, where esterases cleave the ester to release free testosterone. The rate-limiting step is release from the depot, not clearance of the hormone.

Longer ester chains release more slowly, which is why the apparent half-life ranges from days for short esters to weeks for the longest. The clinical consequence is a peak and trough pattern within each dosing interval, and the shape of that pattern is what distinguishes one ester from another far more than any difference in the hormone delivered.

Pulsatile versus sustained signalling is a biological difference.

It is tempting to treat dosing frequency as pure convenience: fewer injections for the same total exposure. For some receptor systems that is roughly true. For others it is not, and the growth hormone axis is the standard counterexample.

Endogenous GH is not secreted continuously. It is released in discrete bursts, predominantly at night, separated by intervals in which concentrations fall very low. Several downstream effects appear to depend on that pattern rather than on average concentration alone, and the trough periods between pulses matter as much as the peaks, in part because sustained receptor occupancy drives desensitisation and altered gene expression profiles.

This has been tested directly. A study in GH-deficient adults compared continuous subcutaneous infusion of GH against daily subcutaneous injections over the long term, examining the IGF-1 system, insulin sensitivity, body composition, and bone and lipoprotein metabolism. The comparison exists precisely because delivering the same drug as a steady level versus as a daily bolus is not assumed to be equivalent.

Peak and trough, and why bloodwork timing matters.

Within any dosing interval, concentration rises to a peak and then falls to a trough immediately before the next administration. The ratio between those two values is the peak to trough ratio, and it is determined by the half-life relative to the dosing interval. A compound dosed at intervals much shorter than its half-life has a nearly flat profile. A compound dosed at intervals comparable to or longer than its half-life swings substantially.

This is the practical reason a lab result without a timestamp relative to the last dose is close to uninterpretable. Two blood draws from the same person on the same protocol can return substantially different numbers purely because one was taken near the peak and one near the trough. Reference ranges published for a given assay were established under particular conditions, and comparing an off-schedule draw against them introduces error that has nothing to do with the person.

Route of administration changes the kinetics, not just the convenience.

The same molecule delivered by different routes produces different concentration curves. Route determines how much reaches circulation (bioavailability), how quickly it gets there (absorption rate and time to peak), and sometimes where it goes.

Why oral peptide bioavailability is so poor.

The gastrointestinal tract is optimised to break peptides into amino acids and absorb those. A therapeutic peptide taken orally faces a sequence of barriers, each of which removes a large fraction of the dose, and the losses multiply rather than add. Reviews of oral peptide and protein delivery describe the same set of obstacles consistently.

Putting it together when you compare two compounds.

Most of the confusion about why compounds are handled differently dissolves once the kinetics are visible. A once weekly injectable and a compound discussed in terms of frequent administration are not different because one is stronger. They are different because one was engineered to persist and the other was not.